STING1 and B-cell non-Hodgkin lymphoma: In a previous murine B cell lymphoma study, vaccination of mice with a STING agonist and anti-GITR yielded a CD8+ T cell response that was reactivated when the mice were re-exposed to A20 B-cell lymphoma cells [145].